A HER2‐targeted Antibody‐Drug Conjugate, RC48‐ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer

More than half of non‐muscle‐invasive bladder cancer (NMIBC) patients eventually relapse even if treated with surgery and BCG without optional bladder‐preserving therapy. This study aims to investigate the antitumor activity and safety of a HER2‐targeted antibody‐drug conjugate, RC48‐ADC, intravesic...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Xuwei, Chen, Xu, Wang, Hongjin, Xu, Qingchun, Xiao, Kanghua, Zhang, Yuanfeng, Chi, Zepai, Liu, Yeqing, Liu, Guangyao, Li, Hong, Fang, Jianmin, Lin, Tianxin, Zhang, Yonghai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646285/
https://www.ncbi.nlm.nih.gov/pubmed/37824205
http://dx.doi.org/10.1002/advs.202302377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646285/
https://www.ncbi.nlm.nih.gov/pubmed/37824205
http://dx.doi.org/10.1002/advs.202302377

Ejemplares similares